Phleum Pratense Pollen

For adults (ages 18 to 65), the standard dosage for Phleum Pratense Pollen sublingual tablets (e.g., GRASTEK) is one tablet (2800 BAU) taken once daily.

• Timing of Initiation: Treatment must be initiated at least 12 weeks before the expected start of the grass pollen season. Clinical data suggests that starting earlier provides superior symptom control during the peak season.
• Duration of Therapy: To achieve long-term desensitization that lasts even after the medication is stopped, healthcare providers typically recommend continuing daily treatment for three consecutive years.

Phleum Pratense Pollen sublingual tablets are FDA-approved for pediatric patients aged 5 through 17 years.

• Standard Dose: The dosage is the same as the adult dose: one 2800 BAU tablet daily.
• Supervision: It is strongly recommended that a parent or caregiver supervise the administration in children to ensure the tablet is held under the tongue for the required duration and not swallowed prematurely.
• Safety: The safety and efficacy in children under the age of 5 have not been established, and use in this age group is generally avoided.

Renal Impairment

No dosage adjustments are required for patients with renal (kidney) impairment. Because the drug is a protein extract degraded by proteases and not cleared by the kidneys, renal function does not impact the safety or efficacy of the sublingual tablets.

Hepatic Impairment

No dosage adjustments are required for patients with hepatic (liver) impairment. The liver's metabolic enzymes (CYP450) are not involved in the processing of allergenic extracts.

Elderly Patients

Clinical trials included a limited number of patients aged 65 and older. While no specific dosage adjustment is recommended, healthcare providers should exercise caution, as elderly patients may have a higher prevalence of comorbid conditions (like heart disease) that could complicate the management of a severe allergic reaction.

Proper administration is critical for the effectiveness of sublingual immunotherapy:

1. 1First Dose: The very first dose must be taken in a healthcare provider's office under medical supervision. The patient must be observed for at least 30 minutes to monitor for signs of a severe systemic allergic reaction (anaphylaxis).
2. 2Administration: Place the tablet under the tongue. Do not swallow for at least one minute to allow the allergens to be absorbed by the oral mucosa.
3. 3Food and Drink: Do not eat or drink anything for at least five minutes after the tablet has dissolved. This prevents the allergen from being washed into the stomach before it can interact with the immune cells in the mouth.
4. 4Hand Hygiene: Wash hands after handling the tablet to avoid accidental transfer of the allergen to the eyes or nose.
5. 5Storage: Store the tablets in their original blister pack at room temperature (20°C to 25°C / 68°F to 77°F). Protect from moisture.

If a dose is missed, take it as soon as you remember. However, if it is almost time for the next dose, skip the missed dose and resume the regular schedule. Do not take two doses at once to make up for a missed one. If more than one dose is missed, contact your healthcare provider before resuming, as a significant gap in treatment may require a temporary dose adjustment or medical re-evaluation.

An overdose of Phleum Pratense Pollen increases the risk of severe local and systemic allergic reactions. Symptoms may include intense swelling of the tongue or throat, difficulty breathing, or abdominal pain.

• Emergency Measures: If an overdose is suspected and the patient shows signs of a systemic reaction, use an epinephrine auto-injector if prescribed and seek immediate emergency medical care (call 911).

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop treatment without medical guidance, as this can affect the success of the desensitization process.

Because Phleum Pratense Pollen is an allergen, the most common side effects are localized allergic reactions in the mouth and throat. These usually occur within the first few days of treatment and often diminish in intensity over time. According to clinical trial data (FDA, 2014), more than 10% of patients experience:

• Oral Pruritus (Itchy Mouth): A tingling or itching sensation on the tongue or roof of the mouth. This is the most frequently reported side effect.
• Throat Irritation: A scratchy or "tight" feeling in the back of the throat.
• Ear Pruritus (Itchy Ears): Itching deep within the ear canal, often linked to the shared nerve pathways of the throat and ears.
• Mouth Edema (Swelling): Mild swelling of the lips or sublingual area.

• Glossodynia: A burning or painful sensation on the tongue.
• Nausea and Abdominal Pain: Some patients may experience mild stomach upset if the allergen is swallowed too quickly.
• Oral Paresthesia: Numbness or a "pins and needles" sensation in the mouth.
• Pharyngeal Edema: Swelling in the back of the throat that does not interfere with breathing.
• Urticaria (Hives): Small, itchy welts that may appear on the skin away from the site of administration.

• Eosinophilic Esophagitis (EoE): A chronic immune system disease where white blood cells (eosinophils) build up in the lining of the esophagus. Symptoms include difficulty swallowing (dysphagia) or chest pain.
• Severe Glossitis: Significant inflammation and swelling of the tongue.
• Laryngopharyngeal Swelling: Swelling that may cause a hoarse voice or a feeling of a lump in the throat.

> Warning: Stop taking Phleum Pratense Pollen and call your doctor or seek emergency care immediately if you experience any of the following symptoms of a systemic allergic reaction (anaphylaxis):

• Difficulty Breathing: Wheezing, shortness of breath, or a tight chest.
• Throat Tightness: A sudden feeling that the airway is closing or severe difficulty swallowing.
• Dizziness or Fainting: A rapid drop in blood pressure (hypotension).
• Rapid Heartbeat: Palpitations or a racing pulse.
• Severe Hives: Widespread itching and redness across the entire body.
• Swelling of the Face or Eyes: Significant angioedema (deep tissue swelling).

The most significant long-term concern with Phleum Pratense Pollen immunotherapy is the potential development of Eosinophilic Esophagitis (EoE). Patients who develop persistent heartburn, difficulty swallowing, or food getting stuck in the throat should be evaluated by a gastroenterologist. Most other side effects, such as oral itching, are transient and typically resolve after the first 1-2 months of daily use as the body becomes desensitized.

Phleum Pratense Pollen sublingual tablets carry an FDA Black Box Warning regarding the risk of severe allergic reactions.

• Anaphylaxis Risk: This medication can cause life-threatening allergic reactions, including anaphylaxis and severe laryngopharyngeal edema.
• Prescribing Requirements: Because of these risks, the drug must only be prescribed to patients who are also prescribed an epinephrine auto-injector (e.g., EpiPen) and are trained on how to use it.
• Contraindications: It must not be given to patients with severe, unstable, or uncontrolled asthma, or those with a history of severe systemic allergic reactions.

Report any unusual or persistent symptoms to your healthcare provider. Monitoring the severity of local reactions during the first week of therapy is essential for patient safety.

Phleum Pratense Pollen is a potent biological extract that must be used with significant caution. It is not a "quick fix" for allergy symptoms but a long-term immune-modifying therapy. Patients must be committed to daily dosing and must have access to emergency medical services if a reaction occurs. It is vital to inform all members of your healthcare team, including your dentist, that you are undergoing allergen immunotherapy.

WARNING: SEVERE ALLERGIC REACTIONS

• Phleum Pratense Pollen can cause life-threatening allergic reactions such as anaphylaxis and severe upper airway swelling.
• Do not take this medication if you have severe, unstable, or uncontrolled asthma.
• Observe patients in the office for at least 30 minutes following the initial dose.
• Patients must be informed of the signs and symptoms of severe allergic reactions and instructed to seek immediate medical care and discontinue the drug if they occur.
• All patients must be prescribed and trained in the use of an auto-injectable epinephrine device.

Allergic Reactions / Anaphylaxis Risk

The risk of systemic reactions is highest during the first few weeks of treatment. Risk factors include a history of severe asthma or previous systemic reactions to other types of immunotherapy. Patients should not start treatment if they are feeling unwell or if their asthma is flaring up.

Asthma

Patients with asthma are at a higher risk for severe respiratory reactions. If a patient experiences a sudden decrease in lung function or an increase in asthma symptoms (wheezing, coughing), they must stop the medication and contact their doctor immediately.

Oral Health and Lesions

Because the medication is absorbed through the oral mucosa, any injury or inflammation in the mouth can increase the speed of absorption and the risk of systemic reactions. Treatment should be temporarily paused if the patient has:

• Oral surgery (including tooth extraction).
• Loss of a deciduous tooth (baby tooth) in children.
• Oral thrush or other infections.
• Significant mouth sores or bleeding gums.

There are no specific laboratory tests (like blood counts or liver panels) required for Phleum Pratense Pollen. However, clinical monitoring is essential:

• Initial Observation: 30-minute medical observation after the first dose.
• Asthma Control: Regular peak flow monitoring or spirometry may be recommended for asthmatic patients.
• Oral Exam: Periodic checks for signs of Eosinophilic Esophagitis or significant tissue irritation.

Phleum Pratense Pollen generally does not cause drowsiness or impair cognitive function. However, if a patient experiences a systemic reaction (dizziness, fainting), they should not drive or operate machinery and must seek emergency help.

There is no direct chemical interaction between alcohol and Phleum Pratense Pollen. However, alcohol can cause vasodilation (widening of blood vessels) in the mouth, which might theoretically increase the absorption rate of the allergen. It is generally advised to avoid consuming alcohol immediately before or after taking the sublingual tablet.

Unlike many medications, Phleum Pratense Pollen does not require a tapering period. It can be stopped abruptly without withdrawal symptoms. However, stopping the medication before the recommended three-year course is completed will likely result in the return of allergy symptoms during the next grass pollen season.

> Important: Discuss all your medical conditions, especially respiratory or esophageal issues, with your healthcare provider before starting Phleum Pratense Pollen.

While there are few absolute "drug-drug" interactions because Phleum Pratense Pollen is a protein, certain medications can make the treatment extremely dangerous:

• Beta-Blockers (e.g., Metoprolol, Propranolol): These medications are contraindicated because they can block the effects of epinephrine. If a patient on a beta-blocker has a severe allergic reaction to the pollen extract, the emergency epinephrine injection may not work effectively to save their life.

• Alpha-Blockers and Ergot Alkaloids: These may also interfere with the body's response to epinephrine during an emergency.
• Tricyclic Antidepressants (TCAs) and MAO Inhibitors: These drugs can potentiate (increase) the effects of epinephrine, potentially leading to dangerously high blood pressure or heart arrhythmias if epinephrine is administered for an allergic reaction.
• Other Immunotherapy: If a patient is receiving "allergy shots" (SCIT) for other allergens (like dust mites or cat dander), the risk of a cumulative systemic reaction is increased. The timing of these treatments must be carefully coordinated by an allergist.

• Inhaled Corticosteroids: While these are often used to manage asthma, any change in the dose of asthma controller medication should be reported to the doctor, as it may indicate that the patient's asthma is not stable enough for immunotherapy.
• Antihistamines: While many patients take antihistamines to manage symptoms, they can sometimes mask the early warning signs of a systemic allergic reaction (like mild itching or hives), potentially delaying the recognition of anaphylaxis.

• High-Acid Foods: Consuming highly acidic foods (like citrus fruits) or very hot liquids immediately after taking the tablet may irritate the sublingual tissue and should be avoided for at least 5-10 minutes.
• Food Allergies: There is a phenomenon known as Oral Allergy Syndrome (OAS). Patients allergic to Timothy grass may also experience itching when eating certain foods like peaches, celery, or tomatoes. Taking the pollen extract may temporarily worsen these cross-reactive food symptoms.

There are no well-documented interactions with common supplements like St. John's Wort or Ginkgo. However, patients should avoid any herbal products that claim to "boost the immune system" (like Echinacea) without consulting their allergist, as these could theoretically interfere with the immune-dampening goals of immunotherapy.

• Skin Prick Testing: Phleum Pratense Pollen therapy will eventually decrease the size of the wheal (bump) during a skin prick test for grass. This is an expected sign of efficacy, not a negative interaction.
• IgE/IgG4 Testing: Therapy will cause a rise in grass-specific IgG4 levels and may cause a transient rise followed by a long-term decrease in grass-specific IgE levels.

Interaction Mechanism Summary

| Interaction Type | Mechanism | Clinical Consequence |

|---|---|---|

| Beta-Blockers | Pharmacodynamic (Antagonism of Epinephrine) | Reduced efficacy of life-saving treatment |

| TCAs/MAOIs | Pharmacodynamic (Potentiation) | Risk of hypertensive crisis during anaphylaxis treatment |

| Other AIT | Cumulative Allergen Load | Increased risk of systemic anaphylaxis |

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for blood pressure, depression, or asthma.

Phleum Pratense Pollen must NEVER be used in the following circumstances:

1. 1Severe or Uncontrolled Asthma: Patients with a Forced Expiratory Volume (FEV1) less than 80% of predicted, or those with frequent exacerbations, are at an unacceptably high risk of fatal respiratory failure if a systemic reaction occurs.
2. 2History of Severe Systemic Allergic Reaction: Anyone who has previously experienced anaphylaxis or severe laryngopharyngeal edema in response to Phleum Pratense extracts.
3. 3Eosinophilic Esophagitis (EoE): Because the medication is absorbed through the esophagus and mouth, it can trigger or worsen this inflammatory condition, leading to permanent esophageal scarring (strictures).
4. 4Hypersensitivity to Excipients: Patients with a known allergy to any of the inactive ingredients in the tablet (such as gelatin or mannitol).

These conditions require a careful risk-benefit analysis by a specialist:

• Active Oral Inflammation: Such as lichen planus, mouth sores, or severe gingivitis. Treatment should be delayed until the mouth has healed.
• Recent Oral Surgery: Including tooth extractions or dental implants. A gap of at least 7 days is typically recommended.
• Autoimmune Diseases: Patients with active systemic autoimmune disorders may have unpredictable immune responses to immunotherapy.
• Malignancy: Patients undergoing active chemotherapy or radiation should generally not start new immunotherapy.

Phleum Pratense (Timothy grass) is part of the Pooideae subfamily. Patients allergic to Timothy grass often show cross-reactivity to other northern grasses, including:

• Orchard grass (Dactylis glomerata)
• Perennial rye grass (Lolium perenne)
• Kentucky bluegrass (Poa pratensis)
• Sweet vernal grass (Anthoxanthum odoratum)

While the extract is standardized for Timothy grass, it may provide some "spillover" protection for these related species, but it also means patients allergic to these grasses are at higher risk for local reactions when taking the Phleum Pratense tablet.

> Important: Your healthcare provider will evaluate your complete medical history, including your asthma control and esophageal health, before prescribing Phleum Pratense Pollen.

• FDA Pregnancy Category: Not formally assigned under the new labeling system, but historically considered Category B/C.
• Risk Summary: There are no adequate and well-controlled studies of Phleum Pratense Pollen in pregnant women. Animal reproduction studies have not shown fetal harm.
• Clinical Considerations: Healthcare providers generally recommend not starting immunotherapy during pregnancy because of the risk of anaphylaxis, which can cause fetal hypoxia (lack of oxygen). However, if a patient is already on a stable maintenance dose and becomes pregnant, the treatment can often be continued if the benefit outweighs the risk.

• Passage into Milk: It is unknown if Phleum Pratense Pollen allergens are excreted in human milk. However, because the active ingredients are large proteins that are degraded in the digestive tract, it is highly unlikely that they would reach the infant in a pharmacologically active form via breast milk.
• Safety: No adverse effects have been reported in nursing infants whose mothers were receiving sublingual immunotherapy.

• Approved Age: FDA-approved for children as young as 5 years old.
• Growth Effects: There is no evidence that allergenic extracts affect growth or development in children.
• Special Dosing: The dose for children is the same as for adults. The main concern is the child's ability to keep the tablet under the tongue for one minute without swallowing.
• Conditions Not Approved For: It is not approved for children under age 5 due to a lack of safety data and the higher risk of choking or improper administration.

• Clinical Data: Clinical trials for GRASTEK included only a small number of patients over age 65.
• Risks: The primary concern in the elderly is the presence of underlying cardiovascular disease. If an elderly patient experiences anaphylaxis, their heart may not tolerate the stress of the reaction or the effects of the emergency epinephrine injection.
• Pharmacokinetics: No age-related changes in the processing of the allergen are expected.

• Adjustment: No dose adjustment is needed. The proteins are broken down into amino acids and do not rely on renal filtration for clearance.
• Dialysis: The drug is not expected to be cleared by dialysis, nor does dialysis affect its local immune mechanism.

• Adjustment: No dose adjustment is needed. The liver's metabolic capacity does not influence the sublingual absorption or the local immune signaling of the pollen extract.

> Important: Special populations, particularly pregnant women and those with heart disease, require individualized medical assessment by an allergy specialist.

Phleum Pratense Pollen acts as a biological response modifier. At the molecular level, it targets the Adaptive Immune System. When the extract is held under the tongue, it is captured by MHC class II-positive dendritic cells in the oral mucosa. These cells migrate to the local lymph nodes and present the Timothy grass allergens (specifically the major allergens Phl p 1 and Phl p 5) to naive T-cells.

This presentation, in the absence of "danger signals," promotes the differentiation of Regulatory T-cells (Tregs). These Tregs produce Interleukin-10 (IL-10), which suppresses the allergic Th2 response. Furthermore, IL-10 signals B-cells to undergo class-switching from IgE production to IgG4 production. The increased levels of IgG4 compete with IgE for allergen binding, effectively preventing the degranulation of mast cells and the subsequent release of histamine and leukotrienes.

• Dose-Response: Clinical trials demonstrated that a dose of 2800 BAU was significantly more effective than lower doses in reducing the Total Combined Score (symptoms + rescue medication use).
• Time to Onset: While some immune changes occur within weeks, the clinical benefit (reduction in sneezing/itching) typically requires at least 8-12 weeks of daily dosing before the start of the pollen season.
• Duration of Effect: Studies have shown that a full three-year course of treatment can provide sustained relief for at least two years after the medication is discontinued.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Local mucosal uptake) |

| Protein Binding | N/A |

| Half-life | N/A (Proteins degraded within minutes to hours) |

| Tmax | N/A (Local action) |

| Metabolism | Local and systemic proteolysis |

| Excretion | Not renally or fecally excreted as intact drug |

• Composition: A freeze-dried extract containing the naturally occurring proteins from the pollen of Phleum pratense.
• Major Allergens: Phl p 1 (a beta-expansin) and Phl p 5 (a ribonuclease-like protein).
• Molecular Weight: Ranges from 10 kDa to over 60 kDa for various protein components.
• Solubility: Highly soluble in water and saliva.

Phleum Pratense Pollen is classified as a Standardized Pollen Allergenic Extract. It is part of the broader category of Allergen Immunotherapy (AIT). Related medications include multi-grass extracts (Oralair), ragweed extracts (Ragwitek), and dust mite extracts (Odactra).